Table 1.
Variables | ECG normal n = 314 |
ECG-4 n = 104 |
p | ECG-5 n = 118 |
p | |
---|---|---|---|---|---|---|
Gender | ||||||
Female | 286 (91.1%) | 92(88.5) | 0.43 | 104 (88.1%) | 0.357 | |
Male | 28 (8.9%) | 12 (11.5%) | 14 (11.9%) | |||
Ethnicity | ||||||
Caucasian | 181 (58.2%) | 59 (57.8%) | 0.09 | 69 (59.5%) | 0.146 | |
Black | 51 (16.4%) | 26 (25.5%) | 27 (23.3%) | |||
Asian | 38 (12.2%) | 10 (9.8%) | 12 (10.3%) | |||
Others | 41 (13.2%) | 7 (6.4) | 8 (6.9%) | |||
Age at SLE diagnosis (years) | 29.6 ± 11.3 | 30.66 ± 11.01 | 0.42 | 30.46 ± 11.86 | 0.50 | |
Age at ECG (years) | 44.87 ± 12.9 | 50.14 ± 14.1 | <0.001 | 49.95 ± 15.01 | <0.001 | |
Disease duration at ECG (years) | 15.23 ± 10.2 | 19.48 ± 11.03 | <0.001 | 19.49 ± 11.44 | <0.001 | |
Follow-up duration at ECG (years) | 10.57 ± 9.4 | 13.69 ± 11.29 | 0.006 | 13.41 ± 11.24 | 0.008 | |
SLEDAI-2 K at the first visit | 9.24 ± 8.3 | 10.2 ± 7.78 | 0.30 | 9.82 ± 7.67 | 0.52 | |
SDI | 0.27 ± 0.7 | 0.44 ± 0.92 | 0.07 | 0.44 ± 0.90 | 0.06 | |
Cumulative glucocorticoid (g) | 5.24 ± 16.5 | 9.16 ± 31.25 | 0.10 | 8.96 ± 29.85 | 0.10 | |
Treated with antimalarials | 147 (46.8%) | 51 (49.0%) | 0.69 | 59 (50.0%) | 0.55 | |
Treated with immunosuppressives | 93 (29.6%) | 33 (31.7%) | 0.68 | 37 (31.4%) | 0.73 | |
Hypertension | 153 (48.7%) | 65 (62.5%) | 0.015 | 74 (63.6%) | 0.006 | |
Hyperlipidemia on statins ever before ECG | 87 (27.7%) | 40 (38.5%) | 0.039 | 44(37.3%) | 0.05 | |
DM 3 years prior to ECG | 16 (5.1%) | 4 (3.8%) | 0.60 | 4 (3.4%) | 0.45 | |
Smoking ever prior to ECG | 91 (29%) | 30 (28.8%) | 0.97 | 34 (28.8%) | 0.91 |
Values are shown as mean ± SD or n (%) as appropriate
p values are from t test for means, Chi-Square test for binary variables, and Cochran-Armitage trend test for categorical variables
DM diabetes mellitus, ECG electrocardiogram, SDI SLICC/American College of Rheumatology Damage Index, SLE systemic lupus erythematosus, SLEDAI-2 K SLE Disease Activity Index 2000